Neoplastic Syndrome Completed Phase 2 Trials for Tazarotene (DB00799)

Also known as: Neoplastic disease (disorder)

IndicationStatusPhase
DBCOND0028594 (Neoplastic Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00489086Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the FaceTreatment